SLDB — Solid Biosciences Inc. stock price, charts and financials

QT71Solid Biosciences Inc.

Solid Biosciences Inc. (NASDAQ: SLDB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
8.02
-0.04-0.50%
OverviewShort InterestFilings
SLDBQT71Solid Biosciences Inc.·NASDAQ
8.02-0.50%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-11.56Insider Own-Shs Outstand98.45MPerf Week2.94%
Market Cap793.50MForward P/E-EPS next Y-1.93Insider Trans-0.64%Shs Float78.20MPerf Month-20.98%
Enterprise Value516.43MPEG-EPS next Q-Inst Own-Short Float22.59%Perf Quarter11.02%
Income-171.95MP/S0.00EPS this Y83.27%Inst Trans-Short Ratio10.61Perf Half Y22.12%
Sales15.00MP/B2.37EPS next Y0.23%ROA-45.35%Short Interest17.67MPerf YTD42.91%
Book/sh-P/C-EPS next 5Y-ROE-74.45%52W High11.39 -29.61%Perf Year14.00%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-49.76%52W Low3.77 112.66%Perf 3Y77.53%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility6.30% 5.79%Perf 5Y-80.67%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-277.78%Oper. Margin0.00%ATR (14)0.55Perf 10Y-
Dividend Ex-Date-Quick Ratio13.10Sales Y/Y TTM-Profit Margin0.00%RSI (14)41.91Recom2.24
Dividend Gr. 3/5Y-Current Ratio13.10EPS Q/Q11.86%SMA20-11.81%Beta2.35Target Price17.00
Payout0.00%Debt/Eq0.06Sales Q/Q-SMA50-2.72%Rel Volume0.62Prev Close8.06
Employees121LT Debt/Eq0.11EarningsAug 11SMA20018.57%Avg Volume1.71MPrice8.02
IPO DateJan 26, 2018Option/ShortYes / YesEPS/Sales Surpr.-21.33% -Net Debt/EBITDA1.46Volume1,060,556Change-0.50%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedPiper SandlerOverweight$20 → $18
May-13-26ReiteratedWedbushOutperform$16
Dec-04-25InitiatedNeedhamBuy$16
Nov-04-25ReiteratedBarclaysOverweight$18 → $9.00
Jul-21-25ReiteratedCantor Fitzgerald$16
Jul-15-24UpgradeJP MorganNeutral → Overweight
Jun-24-24UpgradeLeerink PartnersMarket Perform → Outperform$12
May-31-24ReiteratedPiper SandlerOverweight$20
May-16-24ReiteratedBarclaysOverweight$18
Mar-14-24UpgradePiper SandlerNeutral → Overweight
Latest News
Company

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue15000814000
Cost of Goods Sold Incl. D&A022300432
Gross Profit15-2-2-3814-4-3-2
Selling, General and Administrative Excl. Other283933282927222518
Research and Development7214096777859659558
Other Operating Expense3-1-2-380-4-10
Operating Income-87-179-130-104-106-72-86-119-76
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)0558200-221
Net Income Before Taxes-87-174-125-96-86-72-88-117-75
Income Taxes
000000000
Consolidated Net Income-87-174-125-96-86-72-88-117-75
Net Income From Continuing Operations-87-174-125-96-86-72-88-117-75
Net Income-87-174-125-96-86-72-88-117-75
EPS (Recurring)-11.60-1.99-3.06-4.83-10.10-10.14-25.50-43.05-33.73
EPS (Basic, Before Extraordinaries)-11.60-1.99-3.06-4.83-10.10-10.14-25.50-43.05-33.73
EPS (Diluted)-11.56-1.99-3.06-4.83-10.10-10.14-25.50-43.05-33.73
EBITDA-83-173-122-93-97-69-84-116-76
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio4.28———6.0513.13———
Gross Margin100.00———100.00100.00———
Operating Margin-580.00———-1,325.00-514.29———
Net Margin-580.00———-1,075.00-514.29———
Shares Outstanding888412097332
Market Capitalization6449616412348184341200804
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$12.40$9.69$6.98$4.27$1.56● Close Price0.00M0.62M1.25M1.87M2.50MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SMITH IAN FDirectorJul 02 '26Option Exercise0.003,4400138,145Jul 07
SMITH IAN FDirectorApr 02 '26Option Exercise0.003,4410134,705Apr 02
Howton David TChief Operating OfficerFeb 18 '26Sale5.827,46943,494105,077Feb 18
Cumbo AlexanderPresident and CEOFeb 18 '26Sale5.8216,64496,923235,405Feb 18
Hanrahan JessieChief Regulatory OfficerFeb 18 '26Sale5.824,13424,07474,318Feb 18
Ganot IlanDirectorFeb 18 '26Sale5.822,65815,47827,474Feb 18
Herzich PaulChief Technology OfficerFeb 18 '26Sale5.823,61621,05772,638Feb 18
Brooks GabrielChief Medical OfficerFeb 18 '26Sale5.820089,466Feb 18
Tan KevinCFO & TreasurerFeb 18 '26Sale5.825,40431,46999,422Feb 18
Howton David TChief Operating OfficerFeb 13 '26Option Exercise0.0014,6870112,546Feb 18
Cumbo AlexanderPresident and CEOFeb 13 '26Option Exercise0.0030,0310252,049Feb 18
Brooks GabrielChief Medical OfficerFeb 13 '26Option Exercise0.0010,937095,029Feb 18
Hanrahan JessieChief Regulatory OfficerFeb 13 '26Option Exercise0.008,125078,452Feb 18
Herzich PaulChief Technology OfficerFeb 13 '26Option Exercise0.007,187076,254Feb 18
Tan KevinCFO & TreasurerFeb 13 '26Option Exercise0.0010,6250104,826Feb 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.